$NVIDIA (NVDA.US)$ NVIDIA’s OpenUSD initiative is poised to revolutionize the 3D content creation and digital twin industries by providing a universal, scalable, and open-source framework for interoperability. As the demand for AI-driven simulations, metaverse applications, and real-time collaboration grows, OpenUSD positions NVIDIA at the heart of a booming ecosystem spanning gaming, VFX, industrial design, and robotics. W...

$Tesla (TSLA.US)$ Isn't it a bit unethical for me to deceive the royalty?

$Tesla (TSLA.US)$
I do not want to measure the lows again before today's close. Guys, do not look at how low the price is to be empty. Those who take a blank near the previous day's low will benefit from closing without having to chase after empty, the sales volume is not good. Do not think that the stock price is lower or lower, and more people do not need to chase after the open. And remember not to chase the empty anymore, the periphery is currently below the bottom and the sun should also enter the bounce zone during the low price compression period. If there is no longer a rebound as soon as the big plate flips into the open, then the stock will have to stop, by the time the long line trend will have to be broken, which is a serious Tesla The ride-hailing team should also be vigilant, and Musk should know that, too.
Do good interval maneuvers to earn back the lost money slowly, but remember that the rebound ends as soon as Nastak goes into the air, he will still fall, but not now he has fallen to the bottom.

$Palantir (PLTR.US)$
88PUT
was scared this morning, gotta bounce

$BYD COMPANY (01211.HK)$ $BYD Company ADR (BYDDY.US)$
BYD has pledged to work with Tesla to combat petrol cars, while insisting that Beijing was "more open" to foreign business than the West.
"Our common enemy is the internal combustion engine car. We need to work together . . . to make the industry change," said BYD's executive vice-president Stella Li in an interview with the Financial Times.
Despite her comments, the two carmakers are vyi...

$PHARMA (7081.MY)$
According to Pharmaniaga Berhad (hereinafter referred to as Pharmaniaga) financial report and related announcements for the fourth quarter of 2024, here are some key points of analysis to help determine whether it is worth investing in the company:
1. Financial performance.
Revenue growth: In the fourth quarter of 2024, revenue was 0.926 billion Ringgit, an increase of 17.3% year-on-year. Total revenue for the year was 3.759 billion Ringgit, a year-on-year increase of 10.4%. The revenue growth mainly came from the addition of new products in the franchise Business and price adjustments, as well as increased demand in the Indonesian market.
Profitability: In the fourth quarter of 2024, the pre-tax profit was 13.3 million Ringgit, a significant improvement compared to the loss of 37.4 million Ringgit in the same period of 2023. The total pre-tax profit for the year was 0.194 billion Ringgit, compared to a loss of 78.2 million Ringgit in 2023, indicating a strong recovery.
Earnings per Share (EPS): The basic EPS for the full year of 2024 was 9.15 cents, compared to a loss of 5.86 cents in 2023, showing a significant improvement in the company's profitability.
2. Business Highlights
Franchise Business: Pharmaniaga's franchise agreement with the Ministry of Health of Malaysia is one of its core businesses. In 2024, the company successfully increased the number of products in the franchise product list and conducted...